Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: Immunol Rev. 2009 May;229(1):337–355. doi: 10.1111/j.1600-065X.2009.00773.x

Table 1.

FDA Approved Treatments for MS and Immunoglobulin-Derived Therapeutics.

Brand Name Chemical Name Manufacturer/Distributor Year of FDA Approval Indication
Avonex Interferon β-1a Biogen Idec 1996 Treatment of relapsing forms of MS (once a week via intramuscular injection)
Rebif Interferon β-1a Serono, Inc. 2002 Treatment of relapsing forms of MS (three times a week via subcutaneous injection)
Betaseron Interferon β-1b Berlex Laboratories, Inc. 1993 Treatment of relapsing forms of MS (daily via subcutaneous injection)
Copaxone Glatiramer Acetate TEVA Neuroscience, Inc. 1996 Treatment of relapsing remitting MS (daily via subcutaneous injection)
Novantrone Mitoxantrone Serono, Inc. 2000 Treatment of worsening relapsing remitting, progressive relapsing, and secondary progressive MS (four time a year via intravenous infusion)
Tysabri Anit-VLA-4 mAb Biogen Idec and Elan Pharmaceuticals Withdrawn in Feb. 2005 (currently reapproved by the FDA) Treatment of relapsing forms of MS (every four weeks via intravenous infusion)
Orencia (abatacept) CTLA-4 Ig Bristol-Myers-Squibb 2005 Treatment of rheumatoid arthritis
Rituxan (Rituximab) Anti-CD20 mAb Genentech 1997 Treatment of non-Hodgkin’s lymphoma, also used to treat rheumatoid arthritis
*

The above table is a summary of compiled information by the National Multiple Sclerosis Society, for further information see www.nationalmssociety.org/treatments.asp.